Physician profile
Omeed Warej
NPI 1821356692
$3,838.65
in general payments reported to CMS, 2019-2025
33 companies · $1,591 in 2025
The $1,591 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $122 · 2021: $307 · 2022: $401 · 2023: $411 · 2024: $813 · 2025: $1,591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,815.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,149.73 | 2021-2025 | |
| Amgen INC. | $450.35 | 2019-2025 | Repatha, Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $258.24 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.72 | 2022-2025 | Jardiance, Ofev |
| Pfizer INC. | $171.97 | 2019-2025 | |
| Boston Scientific Corporation | $161.81 | 2023 | Watchman Flx |
| Janssen Pharmaceuticals, INC | $137.84 | 2019-2022 | |
| Allergan, INC. | $130.95 | 2019-2020 | |
| Verona Pharma, INC. | $111.33 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $100.96 | 2024-2025 | |
| Edwards Lifesciences Corporation | $95.69 | 2024-2025 | Sapien 3 Ultra Resilia |
| Heartflow, INC. | $92.51 | 2024-2025 | |
| Novo Nordisk INC | $74.95 | 2025 | Wegovy, Rivfloza, Ozempic |
| Mallinckrodt Hospital Products INC. | $70.49 | 2025 | Acthar |
| Esperion Therapeutics, INC. | $68.88 | 2024-2025 | Nexletol |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $63.92 | 2022-2025 | Assure Wcd |
| Electromed, INC. | $59.74 | 2024-2025 | Smartvest |
| Ani Pharmaceuticals, INC. | $51.43 | 2024-2025 | Purified Cortrophin Gel |
| Kiniksa Pharmaceuticals International, Plc | $51.39 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $46.34 | 2023-2024 | |
| Insmed, INC. | $33.23 | 2025 | Arikayce |
| Merck Sharp & Dohme LLC | $30.13 | 2025 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $29.57 | 2023 | Dupixent |
| Dexcom, INC. | $26.28 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $25.95 | 2025 | Cologuard Collection Kit |
| Irhythm Technologies, INC. | $24.99 | 2024 | Zio Monitor, Zio Xt Patch |
| Alnylam Pharmaceuticals INC. | $24.09 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.39 | 2020 | |
| Kiniksa Pharmaceuticals, Ltd. | $22.13 | 2023 | Arcalyst |
| Lilly USA, LLC | $19.23 | 2025 | Mounjaro, Zepbound |
| Azurity Pharmaceuticals, INC. | $17.43 | 2024 | Edarbi |
| Lexicon Pharmaceuticals, INC. | $17.17 | 2024 | |
| Paratek Pharmaceuticals, INC. | $15.82 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omeed Warej listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.